STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 90 filers reported holding STOKE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $57,587 | -62.9% | 14,616 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $155,368 | +60.5% | 14,616 | +25.8% | 0.00% | 0.0% |
| Q1 2023 | $96,803 | -9.8% | 11,621 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $107,262 | -28.1% | 11,621 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $149,214 | -2.8% | 11,621 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $153,513 | -37.2% | 11,621 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $244,622 | +39.1% | 11,621 | +58.5% | 0.00% | +100.0% |
| Q4 2021 | $175,895 | -5.7% | 7,332 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $186,526 | -24.4% | 7,332 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $246,795 | +16.0% | 7,332 | +33.9% | 0.00% | 0.0% |
| Q1 2021 | $212,727 | -37.3% | 5,477 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $339,191 | +29.6% | 5,477 | -29.9% | 0.00% | 0.0% |
| Q3 2020 | $261,624 | +40.5% | 7,812 | 0.0% | 0.00% | +50.0% |
| Q2 2020 | $186,160 | +4.1% | 7,812 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $178,895 | +32.7% | 7,812 | +64.0% | 0.00% | +200.0% |
| Q4 2019 | $134,860 | – | 4,762 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |